ZA201503603B - Composition for immediate and extended release - Google Patents

Composition for immediate and extended release

Info

Publication number
ZA201503603B
ZA201503603B ZA2015/03603A ZA201503603A ZA201503603B ZA 201503603 B ZA201503603 B ZA 201503603B ZA 2015/03603 A ZA2015/03603 A ZA 2015/03603A ZA 201503603 A ZA201503603 A ZA 201503603A ZA 201503603 B ZA201503603 B ZA 201503603B
Authority
ZA
South Africa
Prior art keywords
immediate
composition
extended release
extended
release
Prior art date
Application number
ZA2015/03603A
Other languages
English (en)
Inventor
Arne Hagsten
Amol Vilasrao Somwanshi
Rambabu Boorugu
Umesh Vinayakrao Barabde
Rajan Verma
Varinder Ahuja
Kristin Wannerberger
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of ZA201503603B publication Critical patent/ZA201503603B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2015/03603A 2012-11-21 2015-05-21 Composition for immediate and extended release ZA201503603B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3575DE2012 2012-11-21
IN3947DE2012 2012-12-20
PCT/EP2013/074373 WO2014079922A1 (en) 2012-11-21 2013-11-21 Composition for immediate and extended release

Publications (1)

Publication Number Publication Date
ZA201503603B true ZA201503603B (en) 2016-01-27

Family

ID=49619947

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/03603A ZA201503603B (en) 2012-11-21 2015-05-21 Composition for immediate and extended release

Country Status (18)

Country Link
EP (1) EP2922525A1 (Direct)
JP (1) JP2016500088A (Direct)
KR (1) KR20150085826A (Direct)
CN (1) CN104797240A (Direct)
AR (1) AR093585A1 (Direct)
AU (1) AU2013349682A1 (Direct)
BR (1) BR112015011430A2 (Direct)
CA (1) CA2891365A1 (Direct)
EA (1) EA201590805A1 (Direct)
HK (1) HK1213779A1 (Direct)
IL (1) IL238648A0 (Direct)
IN (1) IN2015DN03984A (Direct)
MX (1) MX2015006399A (Direct)
PH (1) PH12015501096A1 (Direct)
SG (2) SG10201703388TA (Direct)
TW (1) TW201422254A (Direct)
WO (1) WO2014079922A1 (Direct)
ZA (1) ZA201503603B (Direct)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016001030A (es) 2013-07-23 2016-10-07 Allergan Inc Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
KR20150144209A (ko) * 2014-06-16 2015-12-24 훼링 비.브이. 안정화된 데스모프레신 또는 이의 약학적으로 허용가능한 염을 함유 약학 조성물
ES2923438T3 (es) * 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
AU2015377223A1 (en) 2015-01-12 2017-08-31 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3344240A4 (en) * 2015-09-01 2019-09-04 Wellesley Pharmaceuticals, LLC FORMULATION WITH EXTENDED, DELAYED AND IMMEDIATE RELEASE, METHOD FOR THE PRODUCTION AND USE THEREOF
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
SG11201805530RA (en) * 2015-09-30 2018-07-30 Wellesley Pharmaceuticals Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
EP3389661A4 (en) * 2015-12-18 2019-12-18 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING THE FREQUENCY OF URINATION, METHOD FOR THE PRODUCTION AND USE THEREOF
KR20220100077A (ko) 2016-04-21 2022-07-14 발큐리아 에이비 암의 예비치료용 조성물 및 방법
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3568124A1 (en) 2017-01-11 2019-11-20 Ferring B.V. A fast disintegrating pharmaceutical composition
WO2019039836A2 (ko) * 2017-08-22 2019-02-28 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
IL315049A (en) * 2024-08-15 2026-03-01 Prilenia Neurotherapeutics Ltd Taste-masking compounds containing pridopidine, their use and method for their preparation
US12389928B1 (en) * 2024-10-25 2025-08-19 Mccormick & Company, Inc. Flavor-changing product
CN120247191A (zh) * 2025-03-10 2025-07-04 天津大学 一种尿液废水防腐新型缓释产品及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4052997A (en) 1996-07-19 1998-02-10 Clarke-Garegg, Margaret A. Levan derivatives, their preparation, composition and applications including medical and food applications
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
PT1501534E (pt) * 2002-05-07 2006-09-29 Ferring Bv Formulacoes farmaceuticas
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
CN100366294C (zh) 2004-04-30 2008-02-06 量子高科(北京)研究院有限公司 一种口腔速溶制剂及其生产方法
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
CN102245171A (zh) * 2008-11-10 2011-11-16 株式会社爱茉莉太平洋 缓释微粒及其制备方法
EP2459180A1 (en) * 2009-07-31 2012-06-06 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
MX341200B (es) * 2010-03-29 2016-08-11 Ferring Bv Composicion farmaceutica de disolucion rapida.
MX356601B (es) * 2010-03-30 2018-05-29 Productos Maver S A De C V Combinación farmacéutica con efecto antimigrañoso, en presentación sólida de liberación diferenciada.
US20120135050A1 (en) * 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
SG11201503913TA (en) 2015-06-29
WO2014079922A1 (en) 2014-05-30
IL238648A0 (en) 2015-06-30
AU2013349682A1 (en) 2015-06-04
KR20150085826A (ko) 2015-07-24
CN104797240A (zh) 2015-07-22
JP2016500088A (ja) 2016-01-07
HK1213779A1 (zh) 2016-07-15
EP2922525A1 (en) 2015-09-30
IN2015DN03984A (Direct) 2015-10-02
AR093585A1 (es) 2015-06-10
EA201590805A1 (ru) 2015-11-30
SG10201703388TA (en) 2017-05-30
PH12015501096A1 (en) 2015-07-27
MX2015006399A (es) 2015-07-21
TW201422254A (zh) 2014-06-16
BR112015011430A2 (pt) 2017-07-11
CA2891365A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
IL238648A0 (en) The vehicle for immediate and extended release
IL237309A0 (en) Benzocyclooctyne compounds and uses thereof
GB2506426B (en) Composition
GB201200707D0 (en) Composition
GB2498803B (en) Composition
AP3681A (en) Modified release formulations for oprozomib
EP2878295A4 (en) COMPOSITION
GB201218954D0 (en) Composition
GB2508825B (en) Composition
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
GB201206035D0 (en) Composition
HRP20190326T1 (hr) Pripravak
GB201210530D0 (en) Extended release formulations
IL236357A0 (en) The composition of misoprostol
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201218195D0 (en) Composition
GB201208133D0 (en) Composition
GB201311517D0 (en) Composition
LT2830587T (lt) Odą apsauganti ir odos pusiausvyrą palaikanti kompozicija
SG11201405751TA (en) Composition
GB201210989D0 (en) Composition and device
GB201215414D0 (en) Composition and use
HUP1100207A2 (en) Modified release composition
GB201223526D0 (en) Composition